HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

vanucizumab

targets both Ang-2 and VEGF-A; in clinical trials (2016)

Also Known As:

RG-7221; RG7221; RO-5520985; RO5520985

Networked: 5 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Krieter, Oliver: 4 articles (02/2021 - 01/2018)
2.	Heil, Florian: 3 articles (02/2021 - 01/2018)
3.	Lahr, Angelika: 3 articles (02/2021 - 01/2018)
4.	Lechner, Katharina: 3 articles (02/2021 - 01/2018)
5.	Rossomanno, Simona: 3 articles (02/2021 - 01/2018)
6.	Hidalgo, Manuel: 2 articles (02/2021 - 01/2018)
7.	Le Tourneau, Christophe: 2 articles (02/2021 - 01/2018)
8.	Martinez-Garcia, Maria: 2 articles (02/2021 - 01/2018)
9.	Massard, Christophe: 2 articles (02/2021 - 01/2018)
10.	Ooi, Chia-Huey: 2 articles (02/2021 - 01/2016)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2020 - "Moreover, the performed pharmacokinetic and pharmacodynamic analysis revealed that vanucizumab was bioavailable and affected its intended target, thereby strongly suggesting that Ang-2 is not a relevant therapeutic target in the clinical setting of treatment-naïve metastatic colorectal cancer. " 01/01/2020 - "The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)." 12/01/2020 - "Data were from the McCAVE trial, in which 189 previously untreated patients with metastatic colorectal carcinoma (mCRC) received either bevacizumab (control, C) or vanucizumab (experimental, E), on top of standard chemotherapy. "
2.	Neoplasms (Cancer) 01/01/2018 - "Vanucizumab modulated its angiogenic targets, impacted tumor vascularity, and demonstrated encouraging antitumor activity in this heterogeneous population. " 01/01/2018 - "This first-in-human study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of vanucizumab in adults with advanced solid tumors refractory to standard therapies.Experimental" 02/01/2021 - "Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies." 02/01/2021 - "Vanucizumab is a novel bispecific antibody inhibiting vascular endothelial growth factor (VEGF-A) and angiopoietin-2 (Ang-2) that demonstrated safety and anti-tumor activity in part I of a phase I study of 42 patients with advanced solid tumors. " 01/01/2018 - "First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors."
3.	Hypertension (High Blood Pressure) 01/01/2020 - "Hypertension and peripheral edema were more frequent in the vanucizumab arm. "
4.	Hemorrhage 01/01/2018 - "One dose-limiting toxicity, a fatal pulmonary hemorrhage from a large centrally located mediastinal mass judged possibly related to vanucizumab, occurred with the 19 mg/kg biweekly dose. "
5.	Edema (Dropsy) 01/01/2020 - "Hypertension and peripheral edema were more frequent in the vanucizumab arm. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Bevacizumab (Avastin)
3.	Angiopoietin-2
4.	Biomarkers (Surrogate Marker)
5.	Immunoglobulin E (IgE)
6.	Omalizumab (Xolair)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)